The University of Liège wishes to use cookies or trackers to store and access your personal data, to perform audience measurement. Some cookies are necessary for the website to function. Cookie policy.
Statistics of Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
